Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) EBT (2016 - 2025)

iBio (IBIO) has disclosed EBT for 16 consecutive years, with -$9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 106.07% to -$9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.7 million, a 62.38% decrease, with the full-year FY2025 number at -$18.4 million, down 11.76% from a year prior.
  • EBT was -$9.0 million for Q4 2025 at iBio, down from -$5.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$3.2 million in Q2 2024 to a low of -$10.6 million in Q4 2022.
  • A 5-year average of -$6.3 million and a median of -$5.8 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 167.78% in 2021, then skyrocketed 57.51% in 2023.
  • iBio's EBT stood at -$7.2 million in 2021, then crashed by 46.79% to -$10.6 million in 2022, then surged by 57.51% to -$4.5 million in 2023, then grew by 2.76% to -$4.4 million in 2024, then tumbled by 106.07% to -$9.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's EBT are -$9.0 million (Q4 2025), -$5.7 million (Q3 2025), and -$5.2 million (Q2 2025).